Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Foundry Partners LLC

Foundry Partners LLC lowered its position in Edwards Lifesciences Co. (NYSE:EW) by 6.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,325 shares of the medical research company’s stock after selling 225 shares during the period. Foundry Partners LLC’s holdings in Edwards Lifesciences were worth $219,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in EW. LRI Investments LLC purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $67,000. Lazard Asset Management LLC grew its stake in shares of Edwards Lifesciences by 89.6% during the 1st quarter. Lazard Asset Management LLC now owns 93,629 shares of the medical research company’s stock worth $8,946,000 after purchasing an additional 44,257 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Edwards Lifesciences by 57.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after purchasing an additional 2,390,137 shares in the last quarter. Bellevue Group AG boosted its holdings in Edwards Lifesciences by 8.3% during the first quarter. Bellevue Group AG now owns 1,103,136 shares of the medical research company’s stock worth $105,416,000 after buying an additional 84,138 shares in the last quarter. Finally, Kennedy Capital Management LLC acquired a new position in Edwards Lifesciences during the first quarter worth about $2,440,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on EW shares. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Canaccord Genuity Group lowered their target price on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a report on Friday, October 25th. Oppenheimer reaffirmed an “outperform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Barclays dropped their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Finally, Truist Financial reduced their price target on shares of Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a report on Friday, October 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $70.49 on Friday. The stock’s 50-day moving average is $67.70 and its 200-day moving average is $75.73. The company has a market cap of $41.58 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 3.95 and a beta of 1.12. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the prior year, the business earned $0.59 earnings per share. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insider Activity

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,000 shares of company stock worth $2,657,000. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.